Needham & Company LLC set a $25.00 price target on Amphastar Pharmaceuticals (NASDAQ:AMPH) in a research report sent to investors on Friday. The brokerage currently has a buy rating on the stock.
Several other equities analysts have also recently weighed in on the company. BidaskClub upgraded Amphastar Pharmaceuticals from a buy rating to a strong-buy rating in a report on Wednesday, September 5th. ValuEngine upgraded Amphastar Pharmaceuticals from a hold rating to a buy rating in a report on Friday, August 17th. Wells Fargo & Co restated a buy rating on shares of Amphastar Pharmaceuticals in a report on Friday. Finally, Zacks Investment Research cut Amphastar Pharmaceuticals from a hold rating to a sell rating in a report on Friday, August 10th. Two analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of Buy and a consensus price target of $23.00.
AMPH traded up $0.88 on Friday, hitting $21.59. 735,306 shares of the company’s stock traded hands, compared to its average volume of 117,925. The company has a market capitalization of $890.44 million, a PE ratio of 56.82, a price-to-earnings-growth ratio of 8.77 and a beta of 1.38. Amphastar Pharmaceuticals has a one year low of $14.40 and a one year high of $21.65. The company has a current ratio of 1.94, a quick ratio of 1.24 and a debt-to-equity ratio of 0.11.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its earnings results on Thursday, November 8th. The company reported $0.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.01. The company had revenue of $75.54 million for the quarter, compared to the consensus estimate of $76.84 million. Amphastar Pharmaceuticals had a positive return on equity of 2.15% and a negative net margin of 3.39%. The firm’s quarterly revenue was up 30.5% on a year-over-year basis. During the same quarter last year, the company earned $0.07 EPS. Equities research analysts predict that Amphastar Pharmaceuticals will post 0.1 earnings per share for the current year.
In other Amphastar Pharmaceuticals news, General Counsel Jason B. Shandell sold 16,095 shares of the firm’s stock in a transaction that occurred on Friday, November 9th. The stock was sold at an average price of $20.99, for a total transaction of $337,834.05. Following the completion of the transaction, the general counsel now owns 204,805 shares in the company, valued at approximately $4,298,856.95. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO William J. Peters sold 2,407 shares of the firm’s stock in a transaction that occurred on Thursday, August 16th. The shares were sold at an average price of $17.59, for a total value of $42,339.13. Following the transaction, the chief financial officer now owns 86,836 shares of the company’s stock, valued at approximately $1,527,445.24. The disclosure for this sale can be found here. Insiders have sold a total of 28,502 shares of company stock valued at $558,373 in the last 90 days. 31.50% of the stock is currently owned by company insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AMPH. BlackRock Inc. grew its holdings in Amphastar Pharmaceuticals by 5.9% during the 2nd quarter. BlackRock Inc. now owns 5,720,183 shares of the company’s stock valued at $87,291,000 after buying an additional 318,360 shares in the last quarter. Federated Investors Inc. PA boosted its holdings in shares of Amphastar Pharmaceuticals by 21.6% in the 2nd quarter. Federated Investors Inc. PA now owns 1,276,552 shares of the company’s stock worth $19,480,000 after purchasing an additional 227,142 shares during the period. Cortina Asset Management LLC boosted its holdings in shares of Amphastar Pharmaceuticals by 49.9% in the 2nd quarter. Cortina Asset Management LLC now owns 392,296 shares of the company’s stock worth $5,986,000 after purchasing an additional 130,604 shares during the period. Martingale Asset Management L P purchased a new position in shares of Amphastar Pharmaceuticals in the 3rd quarter worth approximately $2,033,000. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of Amphastar Pharmaceuticals by 5.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,769,533 shares of the company’s stock worth $27,004,000 after purchasing an additional 84,085 shares during the period. Institutional investors and hedge funds own 42.86% of the company’s stock.
About Amphastar Pharmaceuticals
Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and internationally. It operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients.
Featured Article: What does cost of debt say about a company’s financial health?
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.